Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1998-02

AUTHORS

Y. Belkacémi, F. Pène, E. Touboul, B. Rio, V. Leblond, N. C. Gorin, A. Laugier, C. Gemici, M. Housset, M. Ozsahin

ABSTRACT

AimIn order to assess the influence of total-body irradiation (TBI) on the outcome and incidence of complication after bone marrow transplantation (BMT), we retrospectively analyzed our patients treated for acute leukemia and conditioned with TBI prior to BMT.Patients and MethodsBetween 1980 and 1993, 326 patients referred to our department with acute non-lymphoblastic leukemia (ANLL, n=182) and acute lymphoblastic leukemia (ALL, n=144) in complete remission underwent TBI either in single dose (190 patients: 10 Gy administered to the midplane, and 8 Gy to the lungs [STBI]) or in 6 fractions (136 patients: 12 Gy on 3 consecutive days, and 9 Gy to the lungs [FTBI]) before BMT. The male-to-female ratio was 204/122 (1.67), and the median age was 30 years (mean: 30 ± 11, range: 3 to 63). The patients were analyzed according to 3 instantaneous dose rate groups: 118 patients in the LOW group (≤0.048 Gy/min), 188 in the MEDIUM group (> 0.048 and ≤ 0.09 Gy/min), and 20 in the HIGH group (> 0.09 cGy/min). Conditioning chemotherapy consisted of cyclophosphamide (CY) alone in 250 patients, CY and other drugs in 54, and 22 patients were conditioned using combinations without CY. Following TBI, allogeneic and autologous BMT were realized respectively in 118 and 208 patients. Median follow-up period was 68 months (mean: 67 ± 29, range: 24 to 130 months).ResultsFive-year survival, LFS, RI and TRM rates were 42%, 40%, 47%, and 24%, respectively. Five-year LFS was 36% in the STBI and 45% in the FTBI group (p = 0.17). It was 36% in the LOW group, 42% in the MEDIUM group, and 30% in the HIGH group (p > 0.05). Five-year RI was 50% in STBI, 43% in FTBI, 55% in LOW, 41% in MEDIUM, and 44% in HIGH groups (STBI vs. FTBI, p = 0.48; LOW vs. MEDIUM, p = 0.03: MEDIUM vs. HIGH, p = 0.68). TRM was not influenced significantly by the different TBI techniques. When analyzing separately the influence of fractionation and the instantaneous dose rate either in ANLL or ALL patients, no difference in terms of survival and LFS was observed. Fractionation did not influence the 5-year RI both in ANLL and ALL patients. However, among the patients with ANLL, 5-year RI was significantly higher (58%) in the LOW group than the MEDIUM group (31%, p = 0.001), whereas instantaneous dose rate did not significantly influence the RI in ALL patients. The 5-year TRM rate was significantly higher in allogeneic BMT group both in ANLL (37%) and ALL (37%) patients than those treated by autologous BMT (ANLL: 15%, ALL: 18%: p = 0.002 and 0.02, respectively). The 5-year estimated interstitial pneumonitis (IP) and cataract incidence rates were 22% and 19%, respectively, in all patients. IP incidence seemed to be higher in the HIGH group (46%) than the MEDIUM (19%, p = 0.05) or LOW (25%, p = 0.15) groups. Furthermore, cataract incidence was significantly influenced by fractionation (STBI vs. FTBI, 29% vs. 9%; p = 0.003) and instantaneous dose rate (LOW vs. MEDIUM vs. HIGH, 0% vs. 27% vs. 33%; p < 0.0001). Multivariate analyses revealed that the best factors influencing the survival were 1st CR (p = 0.0007), age ≤ 40 years (p = 0.003), and BMT after 1985 (p = 0.008). The RI was influenced independently only by the remission status (p = 0.0002). On the other hand, the TRM rate was lower in patients who did not experience graft-vs.-host disease (GvHD, p < 0.0001), and in those treated after 1985 (p = 0.0005). GvHD was the only independent factor involved in the development of IP (p = 0.01). When considering the cataract incidence, the only independent factor was the instantaneous dose rate (p = 0.0008).ConclusionThe outcome of BMT patients conditioned with TBI for acute leukemia was not significantly influenced by the TBI technique, and TRM seemed to be lower in patients treated after 1985. On the other hand, cataract incidence was significantly influenced by the instantaneous dose rate. More... »

PAGES

92-104

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf03038482

DOI

http://dx.doi.org/10.1007/bf03038482

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039745893

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9487372


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose Fractionation, Radiation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft vs Host Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppression Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy Dosage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sex Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Autologous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Homologous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Whole-Body Irradiation", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413483.9", 
          "name": [
            "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Belkac\u00e9mi", 
        "givenName": "Y.", 
        "id": "sg:person.0674704172.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674704172.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413483.9", 
          "name": [
            "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "P\u00e8ne", 
        "givenName": "F.", 
        "id": "sg:person.07570017064.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07570017064.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413483.9", 
          "name": [
            "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Touboul", 
        "givenName": "E.", 
        "id": "sg:person.01173530150.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173530150.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, H\u00f4tel-Dieu, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411394.a", 
          "name": [
            "Department of Hematology, H\u00f4tel-Dieu, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rio", 
        "givenName": "B.", 
        "id": "sg:person.01245127334.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245127334.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leblond", 
        "givenName": "V.", 
        "id": "sg:person.01342065164.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342065164.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Saint-Antoine, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "H\u00f4pital Saint-Antoine, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gorin", 
        "givenName": "N. C.", 
        "id": "sg:person.07634004764.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07634004764.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413483.9", 
          "name": [
            "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laugier", 
        "givenName": "A.", 
        "id": "sg:person.01157031264.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157031264.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413483.9", 
          "name": [
            "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gemici", 
        "givenName": "C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413483.9", 
          "name": [
            "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Housset", 
        "givenName": "M.", 
        "id": "sg:person.01001160304.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001160304.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413483.9", 
          "name": [
            "Department of Radiation Oncology, H\u00f4pital Tenon, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ozsahin", 
        "givenName": "M.", 
        "id": "sg:person.0627615446.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627615446.74"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1977.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027080276", 
          "https://doi.org/10.1038/bjc.1977.1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1700710", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029125156", 
          "https://doi.org/10.1038/sj.bmt.1700710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-97374-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012802859", 
          "https://doi.org/10.1007/978-3-642-97374-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1998-02", 
    "datePublishedReg": "1998-02-01", 
    "description": "AimIn order to assess the influence of total-body irradiation (TBI) on the outcome and incidence of complication after bone marrow transplantation (BMT), we retrospectively analyzed our patients treated for acute leukemia and conditioned with TBI prior to BMT.Patients and MethodsBetween 1980 and 1993, 326 patients referred to our department with acute non-lymphoblastic leukemia (ANLL, n=182) and acute lymphoblastic leukemia (ALL, n=144) in complete remission underwent TBI either in single dose (190 patients: 10 Gy administered to the midplane, and 8 Gy to the lungs [STBI]) or in 6 fractions (136 patients: 12 Gy on 3 consecutive days, and 9 Gy to the lungs [FTBI]) before BMT. The male-to-female ratio was 204/122 (1.67), and the median age was 30 years (mean: 30 \u00b1 11, range: 3 to 63). The patients were analyzed according to 3 instantaneous dose rate groups: 118 patients in the LOW group (\u22640.048 Gy/min), 188 in the MEDIUM group (> 0.048 and \u2264 0.09 Gy/min), and 20 in the HIGH group (> 0.09 cGy/min). Conditioning chemotherapy consisted of cyclophosphamide (CY) alone in 250 patients, CY and other drugs in 54, and 22 patients were conditioned using combinations without CY. Following TBI, allogeneic and autologous BMT were realized respectively in 118 and 208 patients. Median follow-up period was 68 months (mean: 67 \u00b1 29, range: 24 to 130 months).ResultsFive-year survival, LFS, RI and TRM rates were 42%, 40%, 47%, and 24%, respectively. Five-year LFS was 36% in the STBI and 45% in the FTBI group (p = 0.17). It was 36% in the LOW group, 42% in the MEDIUM group, and 30% in the HIGH group (p > 0.05). Five-year RI was 50% in STBI, 43% in FTBI, 55% in LOW, 41% in MEDIUM, and 44% in HIGH groups (STBI vs. FTBI, p = 0.48; LOW vs. MEDIUM, p = 0.03: MEDIUM vs. HIGH, p = 0.68). TRM was not influenced significantly by the different TBI techniques. When analyzing separately the influence of fractionation and the instantaneous dose rate either in ANLL or ALL patients, no difference in terms of survival and LFS was observed. Fractionation did not influence the 5-year RI both in ANLL and ALL patients. However, among the patients with ANLL, 5-year RI was significantly higher (58%) in the LOW group than the MEDIUM group (31%, p = 0.001), whereas instantaneous dose rate did not significantly influence the RI in ALL patients. The 5-year TRM rate was significantly higher in allogeneic BMT group both in ANLL (37%) and ALL (37%) patients than those treated by autologous BMT (ANLL: 15%, ALL: 18%: p = 0.002 and 0.02, respectively). The 5-year estimated interstitial pneumonitis (IP) and cataract incidence rates were 22% and 19%, respectively, in all patients. IP incidence seemed to be higher in the HIGH group (46%) than the MEDIUM (19%, p = 0.05) or LOW (25%, p = 0.15) groups. Furthermore, cataract incidence was significantly influenced by fractionation (STBI vs. FTBI, 29% vs. 9%; p = 0.003) and instantaneous dose rate (LOW vs. MEDIUM vs. HIGH, 0% vs. 27% vs. 33%; p < 0.0001). Multivariate analyses revealed that the best factors influencing the survival were 1st CR (p = 0.0007), age \u2264 40 years (p = 0.003), and BMT after 1985 (p = 0.008). The RI was influenced independently only by the remission status (p = 0.0002). On the other hand, the TRM rate was lower in patients who did not experience graft-vs.-host disease (GvHD, p < 0.0001), and in those treated after 1985 (p = 0.0005). GvHD was the only independent factor involved in the development of IP (p = 0.01). When considering the cataract incidence, the only independent factor was the instantaneous dose rate (p = 0.0008).ConclusionThe outcome of BMT patients conditioned with TBI for acute leukemia was not significantly influenced by the TBI technique, and TRM seemed to be lower in patients treated after 1985. On the other hand, cataract incidence was significantly influenced by the instantaneous dose rate.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf03038482", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1054450", 
        "issn": [
          "0179-7158", 
          "1439-099X"
        ], 
        "name": "Strahlentherapie und Onkologie", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "174"
      }
    ], 
    "keywords": [
      "total body irradiation", 
      "bone marrow transplantation", 
      "autologous bone marrow transplantation", 
      "only independent factor", 
      "interstitial pneumonitis", 
      "TRM rate", 
      "acute leukemia", 
      "cataract incidence", 
      "complete remission", 
      "marrow transplantation", 
      "TBI technique", 
      "high group", 
      "independent factors", 
      "development of IP", 
      "acute non-lymphoblastic leukemia", 
      "ResultsFive-year survival", 
      "allogeneic BMT group", 
      "low group", 
      "second complete remission", 
      "incidence of complications", 
      "non-lymphoblastic leukemia", 
      "acute lymphoblastic leukemia", 
      "dose rate group", 
      "terms of survival", 
      "MethodsBetween 1980", 
      "conditioning chemotherapy", 
      "FTBI group", 
      "IP incidence", 
      "BMT patients", 
      "host disease", 
      "BMT group", 
      "median age", 
      "remission status", 
      "single dose", 
      "lymphoblastic leukemia", 
      "female ratio", 
      "incidence rate", 
      "instantaneous dose rate", 
      "patients", 
      "ConclusionThe outcome", 
      "cyclophosphamide", 
      "media groups", 
      "multivariate analysis", 
      "ANLL", 
      "leukemia", 
      "incidence", 
      "rate group", 
      "remission", 
      "transplantation", 
      "dose rate", 
      "survival", 
      "sTBI", 
      "AimIn order", 
      "outcomes", 
      "age", 
      "LFS", 
      "influence of fractionation", 
      "group", 
      "GVHD", 
      "pneumonitis", 
      "complications", 
      "chemotherapy", 
      "FTBI", 
      "years", 
      "factors", 
      "disease", 
      "dose", 
      "months", 
      "rate", 
      "drugs", 
      "males", 
      "TRM", 
      "RI", 
      "Department", 
      "status", 
      "best factor", 
      "period", 
      "differences", 
      "hand", 
      "irradiation", 
      "combination", 
      "low", 
      "fractionation", 
      "development", 
      "fraction", 
      "ratio", 
      "technique", 
      "analysis", 
      "influence", 
      "medium", 
      "terms", 
      "Cr", 
      "order"
    ], 
    "name": "Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission", 
    "pagination": "92-104", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039745893"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf03038482"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9487372"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf03038482", 
      "https://app.dimensions.ai/details/publication/pub.1039745893"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_292.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf03038482"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf03038482'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf03038482'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf03038482'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf03038482'


 

This table displays all metadata directly associated to this object as RDF triples.

341 TRIPLES      21 PREDICATES      148 URIs      137 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf03038482 schema:about N05f8f0d878f042cfa33437e358088256
2 N0f9c71df36654877949b962691c32263
3 N168e285194b34dd58621dbb190017d0e
4 N27e1513892c24cab97db4352978a561b
5 N29a665da449044e7a544c24646281ab7
6 N3552a7eb7c744181b187eabac4d62954
7 N394d131ec47341f5bec45dc234f8f6a2
8 N3d5d17827148465db02a59599bcb19da
9 N64cf9b72ef484feaaed720514b008afb
10 N80ef87ffc9464dd1a8c2c370ecbf89c3
11 N82334a0e40a14ee39acf550996bb7281
12 N9458ef01d03e4e3080c76aefa84e0d65
13 N9b3c2c17b9534fef8d6f29bcae735680
14 Na406d68e101a411ba7fa4b1e524bc5f5
15 Na5de8b0c1e7f481bb3f4a033616f4596
16 Naee843edb23f4455bfee2e73d34f8907
17 Nb4e87c89832f4247924ac3939e70ec4e
18 Nb6112767bd8c4e4992aa0ae56ad2b5c7
19 Nbe734599a4df4282bcc0534387cf68b7
20 Nc2e22d9214d14bab84a48d62be6a50a1
21 Nd0e2ad475583483db61e8bca1ab2255c
22 Nd895079c76074433aed9c05725ce9696
23 Ne84e086323c644ce9a68b7a1b6876342
24 Neb3089d741494171b474735605b94473
25 Nf8d863941add425b84df6fe4fe982caa
26 Nfef87b91e273454abdb5e7d78293f0ac
27 anzsrc-for:11
28 anzsrc-for:1102
29 schema:author N01ac4f3311784b40a0fdee09c1dc7290
30 schema:citation sg:pub.10.1007/978-3-642-97374-1
31 sg:pub.10.1038/bjc.1977.1
32 sg:pub.10.1038/sj.bmt.1700710
33 schema:datePublished 1998-02
34 schema:datePublishedReg 1998-02-01
35 schema:description AimIn order to assess the influence of total-body irradiation (TBI) on the outcome and incidence of complication after bone marrow transplantation (BMT), we retrospectively analyzed our patients treated for acute leukemia and conditioned with TBI prior to BMT.Patients and MethodsBetween 1980 and 1993, 326 patients referred to our department with acute non-lymphoblastic leukemia (ANLL, n=182) and acute lymphoblastic leukemia (ALL, n=144) in complete remission underwent TBI either in single dose (190 patients: 10 Gy administered to the midplane, and 8 Gy to the lungs [STBI]) or in 6 fractions (136 patients: 12 Gy on 3 consecutive days, and 9 Gy to the lungs [FTBI]) before BMT. The male-to-female ratio was 204/122 (1.67), and the median age was 30 years (mean: 30 ± 11, range: 3 to 63). The patients were analyzed according to 3 instantaneous dose rate groups: 118 patients in the LOW group (≤0.048 Gy/min), 188 in the MEDIUM group (> 0.048 and ≤ 0.09 Gy/min), and 20 in the HIGH group (> 0.09 cGy/min). Conditioning chemotherapy consisted of cyclophosphamide (CY) alone in 250 patients, CY and other drugs in 54, and 22 patients were conditioned using combinations without CY. Following TBI, allogeneic and autologous BMT were realized respectively in 118 and 208 patients. Median follow-up period was 68 months (mean: 67 ± 29, range: 24 to 130 months).ResultsFive-year survival, LFS, RI and TRM rates were 42%, 40%, 47%, and 24%, respectively. Five-year LFS was 36% in the STBI and 45% in the FTBI group (p = 0.17). It was 36% in the LOW group, 42% in the MEDIUM group, and 30% in the HIGH group (p > 0.05). Five-year RI was 50% in STBI, 43% in FTBI, 55% in LOW, 41% in MEDIUM, and 44% in HIGH groups (STBI vs. FTBI, p = 0.48; LOW vs. MEDIUM, p = 0.03: MEDIUM vs. HIGH, p = 0.68). TRM was not influenced significantly by the different TBI techniques. When analyzing separately the influence of fractionation and the instantaneous dose rate either in ANLL or ALL patients, no difference in terms of survival and LFS was observed. Fractionation did not influence the 5-year RI both in ANLL and ALL patients. However, among the patients with ANLL, 5-year RI was significantly higher (58%) in the LOW group than the MEDIUM group (31%, p = 0.001), whereas instantaneous dose rate did not significantly influence the RI in ALL patients. The 5-year TRM rate was significantly higher in allogeneic BMT group both in ANLL (37%) and ALL (37%) patients than those treated by autologous BMT (ANLL: 15%, ALL: 18%: p = 0.002 and 0.02, respectively). The 5-year estimated interstitial pneumonitis (IP) and cataract incidence rates were 22% and 19%, respectively, in all patients. IP incidence seemed to be higher in the HIGH group (46%) than the MEDIUM (19%, p = 0.05) or LOW (25%, p = 0.15) groups. Furthermore, cataract incidence was significantly influenced by fractionation (STBI vs. FTBI, 29% vs. 9%; p = 0.003) and instantaneous dose rate (LOW vs. MEDIUM vs. HIGH, 0% vs. 27% vs. 33%; p < 0.0001). Multivariate analyses revealed that the best factors influencing the survival were 1st CR (p = 0.0007), age ≤ 40 years (p = 0.003), and BMT after 1985 (p = 0.008). The RI was influenced independently only by the remission status (p = 0.0002). On the other hand, the TRM rate was lower in patients who did not experience graft-vs.-host disease (GvHD, p < 0.0001), and in those treated after 1985 (p = 0.0005). GvHD was the only independent factor involved in the development of IP (p = 0.01). When considering the cataract incidence, the only independent factor was the instantaneous dose rate (p = 0.0008).ConclusionThe outcome of BMT patients conditioned with TBI for acute leukemia was not significantly influenced by the TBI technique, and TRM seemed to be lower in patients treated after 1985. On the other hand, cataract incidence was significantly influenced by the instantaneous dose rate.
36 schema:genre article
37 schema:isAccessibleForFree true
38 schema:isPartOf N3f26db8917e74a1c832085ee10b938d9
39 Nbfab4fc99d3241e0a0392e118f1fb523
40 sg:journal.1054450
41 schema:keywords ANLL
42 AimIn order
43 BMT group
44 BMT patients
45 ConclusionThe outcome
46 Cr
47 Department
48 FTBI
49 FTBI group
50 GVHD
51 IP incidence
52 LFS
53 MethodsBetween 1980
54 RI
55 ResultsFive-year survival
56 TBI technique
57 TRM
58 TRM rate
59 acute leukemia
60 acute lymphoblastic leukemia
61 acute non-lymphoblastic leukemia
62 age
63 allogeneic BMT group
64 analysis
65 autologous bone marrow transplantation
66 best factor
67 bone marrow transplantation
68 cataract incidence
69 chemotherapy
70 combination
71 complete remission
72 complications
73 conditioning chemotherapy
74 cyclophosphamide
75 development
76 development of IP
77 differences
78 disease
79 dose
80 dose rate
81 dose rate group
82 drugs
83 factors
84 female ratio
85 fraction
86 fractionation
87 group
88 hand
89 high group
90 host disease
91 incidence
92 incidence of complications
93 incidence rate
94 independent factors
95 influence
96 influence of fractionation
97 instantaneous dose rate
98 interstitial pneumonitis
99 irradiation
100 leukemia
101 low
102 low group
103 lymphoblastic leukemia
104 males
105 marrow transplantation
106 media groups
107 median age
108 medium
109 months
110 multivariate analysis
111 non-lymphoblastic leukemia
112 only independent factor
113 order
114 outcomes
115 patients
116 period
117 pneumonitis
118 rate
119 rate group
120 ratio
121 remission
122 remission status
123 sTBI
124 second complete remission
125 single dose
126 status
127 survival
128 technique
129 terms
130 terms of survival
131 total body irradiation
132 transplantation
133 years
134 schema:name Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission
135 schema:pagination 92-104
136 schema:productId N3d144cbd233142508a418822a8e16682
137 N69b562c8cb364784acd2b02b04b90b69
138 N6dd74cfaa7654b809fd543e88fb38cb3
139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039745893
140 https://doi.org/10.1007/bf03038482
141 schema:sdDatePublished 2022-10-01T06:30
142 schema:sdLicense https://scigraph.springernature.com/explorer/license/
143 schema:sdPublisher N71a5de4cb54b4cf1ad992afa69507300
144 schema:url https://doi.org/10.1007/bf03038482
145 sgo:license sg:explorer/license/
146 sgo:sdDataset articles
147 rdf:type schema:ScholarlyArticle
148 N01ac4f3311784b40a0fdee09c1dc7290 rdf:first sg:person.0674704172.07
149 rdf:rest Nd8c3539b834f4a2192a4233bf7d3234a
150 N05f8f0d878f042cfa33437e358088256 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Immunosuppressive Agents
152 rdf:type schema:DefinedTerm
153 N0f9c71df36654877949b962691c32263 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Age Factors
155 rdf:type schema:DefinedTerm
156 N168e285194b34dd58621dbb190017d0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Transplantation, Homologous
158 rdf:type schema:DefinedTerm
159 N1a4eb01bb29145d190328ad6c376e897 rdf:first sg:person.01342065164.04
160 rdf:rest N89f07dca84bc43adb94076ad8e10c479
161 N1e6989959bdf4578bdf718fc67ef0df7 rdf:first sg:person.0627615446.74
162 rdf:rest rdf:nil
163 N27e1513892c24cab97db4352978a561b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Survival Rate
165 rdf:type schema:DefinedTerm
166 N29a665da449044e7a544c24646281ab7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Adult
168 rdf:type schema:DefinedTerm
169 N3552a7eb7c744181b187eabac4d62954 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Humans
171 rdf:type schema:DefinedTerm
172 N394d131ec47341f5bec45dc234f8f6a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Leukemia, Myeloid, Acute
174 rdf:type schema:DefinedTerm
175 N3d144cbd233142508a418822a8e16682 schema:name dimensions_id
176 schema:value pub.1039745893
177 rdf:type schema:PropertyValue
178 N3d5d17827148465db02a59599bcb19da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Child
180 rdf:type schema:DefinedTerm
181 N3f26db8917e74a1c832085ee10b938d9 schema:issueNumber 2
182 rdf:type schema:PublicationIssue
183 N64cf9b72ef484feaaed720514b008afb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Whole-Body Irradiation
185 rdf:type schema:DefinedTerm
186 N69b562c8cb364784acd2b02b04b90b69 schema:name pubmed_id
187 schema:value 9487372
188 rdf:type schema:PropertyValue
189 N6dd74cfaa7654b809fd543e88fb38cb3 schema:name doi
190 schema:value 10.1007/bf03038482
191 rdf:type schema:PropertyValue
192 N71a5de4cb54b4cf1ad992afa69507300 schema:name Springer Nature - SN SciGraph project
193 rdf:type schema:Organization
194 N80ef87ffc9464dd1a8c2c370ecbf89c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Sex Factors
196 rdf:type schema:DefinedTerm
197 N82334a0e40a14ee39acf550996bb7281 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Graft vs Host Disease
199 rdf:type schema:DefinedTerm
200 N89f07dca84bc43adb94076ad8e10c479 rdf:first sg:person.07634004764.41
201 rdf:rest Ne8e2bfe7d67f42f392d02910e998d6f4
202 N8adea6961876414689c833eecf3e3da4 rdf:first sg:person.01001160304.17
203 rdf:rest N1e6989959bdf4578bdf718fc67ef0df7
204 N9458ef01d03e4e3080c76aefa84e0d65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Prognosis
206 rdf:type schema:DefinedTerm
207 N9b3c2c17b9534fef8d6f29bcae735680 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Male
209 rdf:type schema:DefinedTerm
210 N9bd31f1083414ec28448c94f0bdc2a4c rdf:first sg:person.01173530150.64
211 rdf:rest Nb3364730f111466fa0bcc467d29543f8
212 Na1394d9f96fe405fba2942c51d4521af rdf:first Nefa02f84ad0e454682517d3532cdf619
213 rdf:rest N8adea6961876414689c833eecf3e3da4
214 Na406d68e101a411ba7fa4b1e524bc5f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Disease-Free Survival
216 rdf:type schema:DefinedTerm
217 Na5de8b0c1e7f481bb3f4a033616f4596 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
218 schema:name Female
219 rdf:type schema:DefinedTerm
220 Naee843edb23f4455bfee2e73d34f8907 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
221 schema:name Dose Fractionation, Radiation
222 rdf:type schema:DefinedTerm
223 Nb3364730f111466fa0bcc467d29543f8 rdf:first sg:person.01245127334.86
224 rdf:rest N1a4eb01bb29145d190328ad6c376e897
225 Nb4e87c89832f4247924ac3939e70ec4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Child, Preschool
227 rdf:type schema:DefinedTerm
228 Nb6112767bd8c4e4992aa0ae56ad2b5c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
229 schema:name Follow-Up Studies
230 rdf:type schema:DefinedTerm
231 Nbe734599a4df4282bcc0534387cf68b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
232 schema:name Middle Aged
233 rdf:type schema:DefinedTerm
234 Nbfab4fc99d3241e0a0392e118f1fb523 schema:volumeNumber 174
235 rdf:type schema:PublicationVolume
236 Nc2e22d9214d14bab84a48d62be6a50a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
237 schema:name Cyclophosphamide
238 rdf:type schema:DefinedTerm
239 Nd0e2ad475583483db61e8bca1ab2255c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
240 schema:name Immunosuppression Therapy
241 rdf:type schema:DefinedTerm
242 Nd895079c76074433aed9c05725ce9696 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
243 schema:name Precursor Cell Lymphoblastic Leukemia-Lymphoma
244 rdf:type schema:DefinedTerm
245 Nd8c3539b834f4a2192a4233bf7d3234a rdf:first sg:person.07570017064.37
246 rdf:rest N9bd31f1083414ec28448c94f0bdc2a4c
247 Ne84e086323c644ce9a68b7a1b6876342 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
248 schema:name Radiotherapy Dosage
249 rdf:type schema:DefinedTerm
250 Ne8e2bfe7d67f42f392d02910e998d6f4 rdf:first sg:person.01157031264.74
251 rdf:rest Na1394d9f96fe405fba2942c51d4521af
252 Neb3089d741494171b474735605b94473 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
253 schema:name Bone Marrow Transplantation
254 rdf:type schema:DefinedTerm
255 Nefa02f84ad0e454682517d3532cdf619 schema:affiliation grid-institutes:grid.413483.9
256 schema:familyName Gemici
257 schema:givenName C.
258 rdf:type schema:Person
259 Nf8d863941add425b84df6fe4fe982caa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
260 schema:name Adolescent
261 rdf:type schema:DefinedTerm
262 Nfef87b91e273454abdb5e7d78293f0ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
263 schema:name Transplantation, Autologous
264 rdf:type schema:DefinedTerm
265 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
266 schema:name Medical and Health Sciences
267 rdf:type schema:DefinedTerm
268 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
269 schema:name Cardiorespiratory Medicine and Haematology
270 rdf:type schema:DefinedTerm
271 sg:journal.1054450 schema:issn 0179-7158
272 1439-099X
273 schema:name Strahlentherapie und Onkologie
274 schema:publisher Springer Nature
275 rdf:type schema:Periodical
276 sg:person.01001160304.17 schema:affiliation grid-institutes:grid.413483.9
277 schema:familyName Housset
278 schema:givenName M.
279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001160304.17
280 rdf:type schema:Person
281 sg:person.01157031264.74 schema:affiliation grid-institutes:grid.413483.9
282 schema:familyName Laugier
283 schema:givenName A.
284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157031264.74
285 rdf:type schema:Person
286 sg:person.01173530150.64 schema:affiliation grid-institutes:grid.413483.9
287 schema:familyName Touboul
288 schema:givenName E.
289 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173530150.64
290 rdf:type schema:Person
291 sg:person.01245127334.86 schema:affiliation grid-institutes:grid.411394.a
292 schema:familyName Rio
293 schema:givenName B.
294 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245127334.86
295 rdf:type schema:Person
296 sg:person.01342065164.04 schema:affiliation grid-institutes:grid.411439.a
297 schema:familyName Leblond
298 schema:givenName V.
299 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342065164.04
300 rdf:type schema:Person
301 sg:person.0627615446.74 schema:affiliation grid-institutes:grid.413483.9
302 schema:familyName Ozsahin
303 schema:givenName M.
304 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627615446.74
305 rdf:type schema:Person
306 sg:person.0674704172.07 schema:affiliation grid-institutes:grid.413483.9
307 schema:familyName Belkacémi
308 schema:givenName Y.
309 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674704172.07
310 rdf:type schema:Person
311 sg:person.07570017064.37 schema:affiliation grid-institutes:grid.413483.9
312 schema:familyName Pène
313 schema:givenName F.
314 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07570017064.37
315 rdf:type schema:Person
316 sg:person.07634004764.41 schema:affiliation grid-institutes:grid.412370.3
317 schema:familyName Gorin
318 schema:givenName N. C.
319 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07634004764.41
320 rdf:type schema:Person
321 sg:pub.10.1007/978-3-642-97374-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012802859
322 https://doi.org/10.1007/978-3-642-97374-1
323 rdf:type schema:CreativeWork
324 sg:pub.10.1038/bjc.1977.1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027080276
325 https://doi.org/10.1038/bjc.1977.1
326 rdf:type schema:CreativeWork
327 sg:pub.10.1038/sj.bmt.1700710 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029125156
328 https://doi.org/10.1038/sj.bmt.1700710
329 rdf:type schema:CreativeWork
330 grid-institutes:grid.411394.a schema:alternateName Department of Hematology, Hôtel-Dieu, Paris, France
331 schema:name Department of Hematology, Hôtel-Dieu, Paris, France
332 rdf:type schema:Organization
333 grid-institutes:grid.411439.a schema:alternateName Groupe Hospitalier Pitié-Salpêtrière, Paris, France
334 schema:name Groupe Hospitalier Pitié-Salpêtrière, Paris, France
335 rdf:type schema:Organization
336 grid-institutes:grid.412370.3 schema:alternateName Hôpital Saint-Antoine, Paris, France
337 schema:name Hôpital Saint-Antoine, Paris, France
338 rdf:type schema:Organization
339 grid-institutes:grid.413483.9 schema:alternateName Department of Radiation Oncology, Hôpital Tenon, Paris, France
340 schema:name Department of Radiation Oncology, Hôpital Tenon, Paris, France
341 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...